



# Standard Guide for Selecting Tests to Evaluate Potential Neurotoxicity of Medical Devices<sup>1</sup>

This standard is issued under the fixed designation F2901; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ε) indicates an editorial change since the last revision or reapproval.

## 1. Scope

1.1 Medical devices may cause adverse effects on the structure and/or function of the nervous system. In this guide, these adverse effects are defined as neurotoxicity. This guide provides background information and recommendations on methods for neurotoxicity testing. This guide should be used with Practice F748, and may be helpful where neurotoxicity testing is needed to evaluate medical devices that contact nervous system tissue or cerebral spinal fluid (CSF).

1.2 *This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.*

## 2. Referenced Documents

### 2.1 ASTM Standards:<sup>2</sup>

F748 Practice for Selecting Generic Biological Test Methods for Materials and Devices

F1904 Practice for Testing the Biological Responses to Particles *in vivo*

### 2.2 Other Referenced Documents:

ISO/AAMI/ANSI 10993-3 :2003 Biological Evaluation of Medical Devices—Part 3: Tests for Genotoxicity, Carcinogenicity, and Reproductive Toxicity<sup>3</sup>

ISO/AAMI/ANSI 10993-5 :2009 Biological Evaluation of Medical Devices—Part 5: Tests for In Vitro Cytotoxicity<sup>3</sup>

ISO 10993-11 : 2006 Biological Evaluation of Medical Devices—Part 11: Tests for Systemic Toxicity

ISO/AAMI/ANSI 10993-18 Biological Evaluation of Medi-

cal Devices—Part 18: Chemical Characterization of Materials<sup>3</sup>

ANSI/AAMI ST72 :2010 Bacterial Endotoxins—Test Methodologies, Routine Monitoring, and Alternatives to Batch Testing<sup>3</sup>

USP <151> Rabbit Pyrogen Test<sup>4</sup>

USP <161> Transfusion and Infusion Assemblies and Similar Medical Devices<sup>4</sup>

## 3. Summary of Guide

3.1 This is an informative guide and should be used with Practice F748.

3.2 The duration of contact between the tissue and medical device should be considered when determining the appropriate panel of testing. This guide may not address neurosurgical instruments or medical devices that have transient incidental contact with the nervous system due to the limited tissue contact duration.

3.3 The evaluation of neurotoxicity should be considered in conjunction with material characterization and other information such as non-clinical tests, clinical studies, post-market experience, and intended use.

## 4. Significance and Use

4.1 The objective of this guide is to recommend a panel of biological tests that can be used in addition to the testing recommended in Practice F748. This guide is designed to detect neurotoxicity caused by medical devices that contact nervous tissue.

4.2 The testing recommendations should be considered for new materials, established materials with different manufacturing methods that could affect nervous tissue response, or materials used in new nervous tissue applications.

4.3 Chemical characterization can be used to evaluate similarity for materials with a history of clinical use in a similar nervous tissue application.

<sup>1</sup> This guide is under the jurisdiction of ASTM Committee F04 on Medical and Surgical Materials and Devices and is the direct responsibility of Subcommittee F04.16 on Biocompatibility Test Methods.

Current edition approved Feb. 1, 2013. Published February 2013. Originally approved in 2012. Last previous edition approved in 2012 as F2901 – 12. DOI: 10.1520/F2901-13.

<sup>2</sup> For referenced ASTM standards, visit the ASTM website, [www.astm.org](http://www.astm.org), or contact ASTM Customer Service at [service@astm.org](mailto:service@astm.org). For *Annual Book of ASTM Standards* volume information, refer to the standard's Document Summary page on the ASTM website.

<sup>3</sup> Available from American National Standards Institute (ANSI), 25 W. 43rd St., 4th Floor, New York, NY 10036, <http://www.ansi.org>.

<sup>4</sup> Available from U.S. Pharmacopeia (USP), 12601 Twinbrook Pkwy., Rockville, MD 20852-1790, <http://www.usp.org>.

## 5. Tests for Neurotoxicity

5.1 Testing should be performed on the final sterilized device, representative samples from the final sterilized device, or materials processed in the same manner as the final sterilized device. Testing of individual materials may be useful for research and development, but the definitive neurotoxicity evaluation should include all materials in the final version of the device. The test article should be exposed to all phases of manufacturing including processing, cleaning, sterilization, and packaging.

5.1.1 A complete description of all device materials and reagents used during manufacturing and processing should be provided with information on the source, purity, and toxicity profile. Chemical characterization studies can provide additional information on the device safety profile. See ISO/AAMI/ANSI 10993-18 for information on chemical characterization of materials.

5.2 The following tests should be considered to assess neurotoxicity of medical devices within the scope of this guide.

5.2.1 *Cytotoxicity*—Cytotoxicity assays are sensitive screening tools that generally serve as a starting point for evaluating medical device biocompatibility. See **X1.4** for information on neuro-cytotoxicity testing.

5.2.2 *Genotoxicity*—Nervous tissue contains proliferating cell populations, and can respond to device implantation with a proliferative response. Nervous tissue is also known to give rise to various tumor types. To ensure that medical devices do not include genotoxic chemicals, the use of a panel of genotoxicity tests is recommended. The panel of genotoxicity tests should include a test for gene mutation in bacteria, an *in-vitro* test with cytogenetic evaluation of chromosomal damage with mammalian cells or an *in-vitro* mouse lymphoma tk assay, and an *in-vivo* test for chromosomal damage using rodent hematopoietic cells. See ISO/AAMI/ANSI 10993-3 for additional information on genotoxicity testing.

5.2.3 *Implantation*—The use of a clinically relevant implantation study is recommended. The implantation site and animal model should be selected and justified according to the intended clinical use of the medical device. The study should include both histopathology and neurobehavioral assessments. In addition to the use of hematoxylin and eosin (H&E), more sensitive and specific histopathological assessments should be considered, including methods that are capable of enhancing and quantification of neurodegeneration, astrogliosis, microglia activation, and myelinopathy. See Polikov et al. (**1**)<sup>5</sup>, Schmued et al. (**2**), and O'Callaghan et al. (**3**) for examples of detection methods using Fluor-Jade for detection of neurodegeneration, glial fibrillary acidic protein (GFAP) for detection of astrogliosis, and Macrophage-1 antigen (MAC-1), Isolectin IB4, or ionized calcium binding adaptor molecule 1 (IBA-1) for detection of microglia activation. Tissue sectioning

should include the implant-tissue interface and include sectioning of sufficient area around the implant to ensure that the potential effects of diffusion of degradable and/or leachable materials are captured in the histological analysis. Consideration should be given to whether cross or transverse sectioning best captures the area of interest depending on the anatomical region. The test period should be determined by the clinical exposure time, or go beyond the point where a tissue response steady state has been reached. The time course of the study should be designed and justified based on the intended clinical use. Finally, a functional observation battery designed to detect signs of neurobehavioral dysfunction is recommended to complement the histopathological assessments.

5.2.4 *Pyrogen Testing*—Pyrogen testing on the final sterilized medical device is recommended to reduce the likelihood of a neuroinflammatory response to the device. Material-mediated pyrogen testing should be conducted using the rabbit pyrogen test (see USP <151> and ISO 10993-11, Annex F). Endotoxin testing with an assay such as the Limulus Amebocyte Lysate (LAL) assay should be conducted in compliance with ANSI/AAMI ST72 and USP <161>.

5.2.5 *Wear Particle Testing*—The proximity of orthopedic spine devices to the spinal cord and nerve roots may warrant evaluation of potential neurotoxicity. Devices capable of generating wear particles should be evaluated if the wear particles have not already been adequately tested for potential neurotoxicity. If particle testing is warranted, an appropriately justified animal study is recommended. See Practice **F1904** and reference by Cunningham (**4**) for examples of particle-mediated neurotoxicity evaluation methods. The animal study should be designed to evaluate local, systemic, and neurobehavioral responses to particles. The spinal cord, nerve roots, surrounding tissue, and distant tissues should be evaluated for signs of toxicity and inflammation. The size, shape, and dose of particles used in the animal study should be representative of the particles expected to be generated clinically.

5.2.6 *Developmental Neurotoxicity*—Neurodevelopment includes critical periods that can have increased sensitivities to neurotoxicants, and neurodevelopment continues into the post-natal period. Therefore, developmental neurotoxicity studies may be considered for medical devices that both potentially leach chemicals of developmental neurotoxicity concern and are indicated for pregnant women with the potential for fetal exposure or are indicated for pediatric patient populations. For guidance on developmental neurotoxicity study design, see Raffaele et al (**5**).

5.2.7 Due to the limitations of testing methods for assessing neurotoxicity, human clinical studies and patient monitoring may also be necessary to adequately evaluate neurological medical device safety, particularly when the predictive value of animal neurotoxicity models is limited.

## 6. Keywords

6.1 astrogliosis; biocompatibility; microglia; myelinopathy; neurodegeneration; neurotoxicity

<sup>5</sup> The boldface numbers in parentheses refer to the list of references at the end of this standard.

## APPENDIX

### (Nonmandatory Information)

#### X1. RATIONALE

X1.1 The primary purpose of this guide is to describe a test battery capable of detecting medical device-mediated neurotoxicity.

X1.2 It is well recognized that the nervous system is a heterogeneous tissue comprised of unique cell types, proteins, and biochemical pathways. The interaction of materials with nervous tissue may adversely affect the structure and/or function of the nervous system. The nervous system has limited capacity for repair, increasing the importance of preclinical detection of potential neurotoxicants used in medical devices.

X1.3 This guide considered the Food and Drug Administration Center for Food Safety and Nutrition Document entitled Toxicological Principles for the Safety Assessment of Food Ingredients: IV.C.10 Neurotoxicity Studies Redbook 2000 (6), and the Environmental Protection Agency document entitled

Health Effects Test Guidelines OPPTS 870.6200 Neurotoxicity Screening Battery (7).

X1.4 *Neuro-Cytotoxicity Testing*—The sensitivity, specificity, and predictivity of neuro-cytotoxicity testing are not well established. In addition, as with traditional cytotoxicity testing, neuro-cytotoxicity testing can yield false negative and false positive results. Despite these potential limitations, evaluation of potential medical device neurotoxicity may be improved by the use of cell lines derived from nervous tissue since these cells are more likely to express nervous tissue-specific toxicant targets. Therefore, consideration should be given to the inclusion of a neuro-cytotoxicity test in addition to traditional cytotoxicity testing. For additional information on *in vitro* techniques for the assessment of neurotoxicity including cell line recommendations, see Harry et al. (8).

#### REFERENCES

- (1) Polikov, V. S., Tresco, P. A., Reichert, W. M., Response of brain tissue to chronically implanted neural electrodes, *J Neurosci Methods*, Vol 148, No. 1, 2005, pp. 1–18.
- (2) Schmued, L. C., Stowers, C. C., Scallet, A. C., Xu, L., Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons, *Brain Res*, Vol 1035, No. 1, 2005, pp. 24–31.
- (3) O’Callaghan, J. P., Sriram, K., Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity, *Expert Opin Drug Saf*, Vol 4, No. 3, 2005, pp. 433–442.
- (4) Cunningham, B. W., Basic scientific considerations in total disc arthroplasty, *Spine J*, Vol 4, No. 6 Suppl, 2004, pp. 219S–230S.
- (5) Raffaele, K. C., Fisher, J. E. Jr., Hancock, S., Hazelden, K., Sobrian, S. K., Determining normal variability in a developmental neurotoxicity test: a report from the ILSI Research Foundation/Risk Science Institute expert working group on neurodevelopmental endpoints, *Neurotoxicol Teratol*, Vol 30, No. 4, 2008, pp. 288–325.
- (6) U.S. Food and Drug Administration Redbook: Toxicological Principles for the Safety Assessment of Food Ingredients, Neurotoxicity Studies, 2000, Chapter IV.C.10.
- (7) U.S. Environmental Protection Agency, Health Effects Test, Guidelines OPPTS 870.6200 Neurotoxicity Screening Battery.
- (8) Harry, J. G., Billingsley, M., Bruinink, A., Campbell, L. L., Classen, W., Dorman, D. C., Galli, C., Ray, D., Smith, R. A., and Tilson, H. A., In Vitro Techniques for the Assessment of Neurotoxicity, *Environ Health Perspect*, Vol 106, No. Suppl 1, 1998, pp. 131–158.

ASTM International takes no position respecting the validity of any patent rights asserted in connection with any item mentioned in this standard. Users of this standard are expressly advised that determination of the validity of any such patent rights, and the risk of infringement of such rights, are entirely their own responsibility.

This standard is subject to revision at any time by the responsible technical committee and must be reviewed every five years and if not revised, either reapproved or withdrawn. Your comments are invited either for revision of this standard or for additional standards and should be addressed to ASTM International Headquarters. Your comments will receive careful consideration at a meeting of the responsible technical committee, which you may attend. If you feel that your comments have not received a fair hearing you should make your views known to the ASTM Committee on Standards, at the address shown below.

This standard is copyrighted by ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959, United States. Individual reprints (single or multiple copies) of this standard may be obtained by contacting ASTM at the above address or at 610-832-9585 (phone), 610-832-9555 (fax), or service@astm.org (e-mail); or through the ASTM website (www.astm.org). Permission rights to photocopy the standard may also be secured from the ASTM website (www.astm.org/COPYRIGHT/).